The N‐terminal domain of gasdermin D induces liver fibrosis by reprogrammed lipid metabolism

Abstract Background The emerging incidence of pathogenic liver conditions is turning into a major concern for global health. Induction of pyroptosis in hepatocytes instigates cellular disintegration, which in turn liberates substantial quantities of pro‐inflammatory intracellular substances, thereby...

Full description

Saved in:
Bibliographic Details
Main Authors: Xue Wang, Chunyou Ning, Xingyi Cheng, Zhengzhong Wu, Dongbo Wu, Xuemei Ding, Cunxiang Ju, Zhihang Zhou, Lingfeng Wan, Wei Zhao, Peiliang Shi
Format: Article
Language:English
Published: Wiley 2025-01-01
Series:Animal Models and Experimental Medicine
Subjects:
Online Access:https://doi.org/10.1002/ame2.12506
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832087824753491968
author Xue Wang
Chunyou Ning
Xingyi Cheng
Zhengzhong Wu
Dongbo Wu
Xuemei Ding
Cunxiang Ju
Zhihang Zhou
Lingfeng Wan
Wei Zhao
Peiliang Shi
author_facet Xue Wang
Chunyou Ning
Xingyi Cheng
Zhengzhong Wu
Dongbo Wu
Xuemei Ding
Cunxiang Ju
Zhihang Zhou
Lingfeng Wan
Wei Zhao
Peiliang Shi
author_sort Xue Wang
collection DOAJ
description Abstract Background The emerging incidence of pathogenic liver conditions is turning into a major concern for global health. Induction of pyroptosis in hepatocytes instigates cellular disintegration, which in turn liberates substantial quantities of pro‐inflammatory intracellular substances, thereby accelerating the advancement of liver fibrosis. Consequently, directing therapeutic efforts towards inhibiting pyroptosis could potentially serve as an innovative approach in managing inflammation related chronic hepatic disorders. Methods GSDMD‐NTki/wt mice and Alb‐creki/wt mice were generated using CRISPR/Cas9 technology. After crossing the two strains together, we induced conditional cell death by doxycycline to construct a mouse model of liver fibrosis. We analyzed differentially expressed genes by RNA sequencing and explored their biological functions. The efficacy of obeticholic acid (OCA) in the treatment of liver fibrosis was assessed. Results Doxycycline‐treated GSDMD‐NTki/wt × Alb‐creki/wt mice showed severe liver damage, vacuolation of hepatocytes, increased collagen fibers, and accumulation of lipid droplets. The expression of liver fibrosis related genes was greatly increased in the doxycycline‐treated mouse liver compared with untreated mouse liver. RNA‐sequencing showed that upregulated differentially expressed genes were involved in inflammatory responses, cell activation, and metabolic processes. Treatment with OCA alleviated the liver fibrosis, with reduced ALT and AST levels seen in the GSDMD‐NTki/wt × Alb‐creki/wt mice. Conclusions We successfully constructed a novel mouse model for liver fibrosis. This GSDMD‐NT‐induced fibrosis may be mediated by abnormal lipid metabolism. Our results demonstrated that we successfully constructed a mouse model of liver fibrosis, and GSDMD‐NT induced fibrosis by mediating lipid metabolism.
format Article
id doaj-art-bd7849bf977f4232aed32842e9c49e0e
institution Kabale University
issn 2576-2095
language English
publishDate 2025-01-01
publisher Wiley
record_format Article
series Animal Models and Experimental Medicine
spelling doaj-art-bd7849bf977f4232aed32842e9c49e0e2025-02-06T03:52:55ZengWileyAnimal Models and Experimental Medicine2576-20952025-01-018111412510.1002/ame2.12506The N‐terminal domain of gasdermin D induces liver fibrosis by reprogrammed lipid metabolismXue Wang0Chunyou Ning1Xingyi Cheng2Zhengzhong Wu3Dongbo Wu4Xuemei Ding5Cunxiang Ju6Zhihang Zhou7Lingfeng Wan8Wei Zhao9Peiliang Shi10GemPharmatech Chengdu Co., Ltd. Chengdu ChinaGemPharmatech Chengdu Co., Ltd. Chengdu ChinaGemPharmatech Chengdu Co., Ltd. Chengdu ChinaGemPharmatech Chengdu Co., Ltd. Chengdu ChinaCenter of Infectious Diseases West China Hospital, Sichuan University Chengdu ChinaGemPharmatech Chengdu Co., Ltd. Chengdu ChinaGempharmatech Shanghai Co., Ltd. Shanghai ChinaDepartment of Gastroenterology the Second Affiliated Hospital of Chongqing Medical University Chongqing ChinaFatty Liver Disease Center of Integrated Chinese and Western Medicine Affiliated Hospital of Nanjing University of Chinese Medicine Nanjing ChinaSchool of Clinical Medicine and The First Affiliated Hospital of Chengdu Medical College Chengdu ChinaGemPharmatech Chengdu Co., Ltd. Chengdu ChinaAbstract Background The emerging incidence of pathogenic liver conditions is turning into a major concern for global health. Induction of pyroptosis in hepatocytes instigates cellular disintegration, which in turn liberates substantial quantities of pro‐inflammatory intracellular substances, thereby accelerating the advancement of liver fibrosis. Consequently, directing therapeutic efforts towards inhibiting pyroptosis could potentially serve as an innovative approach in managing inflammation related chronic hepatic disorders. Methods GSDMD‐NTki/wt mice and Alb‐creki/wt mice were generated using CRISPR/Cas9 technology. After crossing the two strains together, we induced conditional cell death by doxycycline to construct a mouse model of liver fibrosis. We analyzed differentially expressed genes by RNA sequencing and explored their biological functions. The efficacy of obeticholic acid (OCA) in the treatment of liver fibrosis was assessed. Results Doxycycline‐treated GSDMD‐NTki/wt × Alb‐creki/wt mice showed severe liver damage, vacuolation of hepatocytes, increased collagen fibers, and accumulation of lipid droplets. The expression of liver fibrosis related genes was greatly increased in the doxycycline‐treated mouse liver compared with untreated mouse liver. RNA‐sequencing showed that upregulated differentially expressed genes were involved in inflammatory responses, cell activation, and metabolic processes. Treatment with OCA alleviated the liver fibrosis, with reduced ALT and AST levels seen in the GSDMD‐NTki/wt × Alb‐creki/wt mice. Conclusions We successfully constructed a novel mouse model for liver fibrosis. This GSDMD‐NT‐induced fibrosis may be mediated by abnormal lipid metabolism. Our results demonstrated that we successfully constructed a mouse model of liver fibrosis, and GSDMD‐NT induced fibrosis by mediating lipid metabolism.https://doi.org/10.1002/ame2.12506GSDMD‐NTlipid metabolismliver fibrosisNASHpyroptosis
spellingShingle Xue Wang
Chunyou Ning
Xingyi Cheng
Zhengzhong Wu
Dongbo Wu
Xuemei Ding
Cunxiang Ju
Zhihang Zhou
Lingfeng Wan
Wei Zhao
Peiliang Shi
The N‐terminal domain of gasdermin D induces liver fibrosis by reprogrammed lipid metabolism
Animal Models and Experimental Medicine
GSDMD‐NT
lipid metabolism
liver fibrosis
NASH
pyroptosis
title The N‐terminal domain of gasdermin D induces liver fibrosis by reprogrammed lipid metabolism
title_full The N‐terminal domain of gasdermin D induces liver fibrosis by reprogrammed lipid metabolism
title_fullStr The N‐terminal domain of gasdermin D induces liver fibrosis by reprogrammed lipid metabolism
title_full_unstemmed The N‐terminal domain of gasdermin D induces liver fibrosis by reprogrammed lipid metabolism
title_short The N‐terminal domain of gasdermin D induces liver fibrosis by reprogrammed lipid metabolism
title_sort n terminal domain of gasdermin d induces liver fibrosis by reprogrammed lipid metabolism
topic GSDMD‐NT
lipid metabolism
liver fibrosis
NASH
pyroptosis
url https://doi.org/10.1002/ame2.12506
work_keys_str_mv AT xuewang thenterminaldomainofgasdermindinducesliverfibrosisbyreprogrammedlipidmetabolism
AT chunyouning thenterminaldomainofgasdermindinducesliverfibrosisbyreprogrammedlipidmetabolism
AT xingyicheng thenterminaldomainofgasdermindinducesliverfibrosisbyreprogrammedlipidmetabolism
AT zhengzhongwu thenterminaldomainofgasdermindinducesliverfibrosisbyreprogrammedlipidmetabolism
AT dongbowu thenterminaldomainofgasdermindinducesliverfibrosisbyreprogrammedlipidmetabolism
AT xuemeiding thenterminaldomainofgasdermindinducesliverfibrosisbyreprogrammedlipidmetabolism
AT cunxiangju thenterminaldomainofgasdermindinducesliverfibrosisbyreprogrammedlipidmetabolism
AT zhihangzhou thenterminaldomainofgasdermindinducesliverfibrosisbyreprogrammedlipidmetabolism
AT lingfengwan thenterminaldomainofgasdermindinducesliverfibrosisbyreprogrammedlipidmetabolism
AT weizhao thenterminaldomainofgasdermindinducesliverfibrosisbyreprogrammedlipidmetabolism
AT peiliangshi thenterminaldomainofgasdermindinducesliverfibrosisbyreprogrammedlipidmetabolism
AT xuewang nterminaldomainofgasdermindinducesliverfibrosisbyreprogrammedlipidmetabolism
AT chunyouning nterminaldomainofgasdermindinducesliverfibrosisbyreprogrammedlipidmetabolism
AT xingyicheng nterminaldomainofgasdermindinducesliverfibrosisbyreprogrammedlipidmetabolism
AT zhengzhongwu nterminaldomainofgasdermindinducesliverfibrosisbyreprogrammedlipidmetabolism
AT dongbowu nterminaldomainofgasdermindinducesliverfibrosisbyreprogrammedlipidmetabolism
AT xuemeiding nterminaldomainofgasdermindinducesliverfibrosisbyreprogrammedlipidmetabolism
AT cunxiangju nterminaldomainofgasdermindinducesliverfibrosisbyreprogrammedlipidmetabolism
AT zhihangzhou nterminaldomainofgasdermindinducesliverfibrosisbyreprogrammedlipidmetabolism
AT lingfengwan nterminaldomainofgasdermindinducesliverfibrosisbyreprogrammedlipidmetabolism
AT weizhao nterminaldomainofgasdermindinducesliverfibrosisbyreprogrammedlipidmetabolism
AT peiliangshi nterminaldomainofgasdermindinducesliverfibrosisbyreprogrammedlipidmetabolism